Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.2.2
Commitments and Contingencies (Details Narrative)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2021
USD ($)
Jul. 31, 2012
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2022
EUR (€)
Jun. 30, 2021
USD ($)
Loss Contingencies [Line Items]              
Research and development expenses     $ 5,648,952 $ 3,887,261 $ 16,320,090   $ 11,598,835
Payment to acquire in process research and development         871,877  
Discovery Collaboration Agreements [Member]              
Loss Contingencies [Line Items]              
Research and development expenses     $ 500,000   $ 500,000    
Discovery Collaboration Agreements [Member] | XOMA [Member]              
Loss Contingencies [Line Items]              
Milestone payments   $ 3,800,000          
Cellca Agreement [Member]              
Loss Contingencies [Line Items]              
Description of milestone payments         The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised. The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.  
The Cellca Agreement [Member]              
Loss Contingencies [Line Items]              
Milestone payments         $ 600,000    
The Cellca Agreement [Member] | In Process Research and Development [Member]              
Loss Contingencies [Line Items]              
Payment of license fee acquired         100,000    
The Cellca Agreement [Member] | Minimum [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation         100,000    
The Cellca Agreement [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation         600,000    
The Brink Agreement [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation $ 100,000            
Payment of license fee acquired $ 100,000            
The Brink Agreement [Member] | In Process Research and Development [Member]              
Loss Contingencies [Line Items]              
Payment of license fee acquired         100,000    
The InvivoGen Agreement [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation         100,000 € 100,000  
The InvivoGen Agreement [Member] | In Process Research and Development [Member]              
Loss Contingencies [Line Items]              
Payment for annual license fee obligation         100,000    
The ProteoNic Agreement [Member]              
Loss Contingencies [Line Items]              
Milestone payments         1,300,000 1,200,000  
Payment for annual license fee obligation         26,000 € 25,000  
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]              
Loss Contingencies [Line Items]              
Milestone payments         1,000,000.0    
Payment to acquire in process research and development         $ 100,000